PRQR vs. GOSS, SKYE, MCRB, PRLD, CAPR, IXHL, CRVO, GLSI, IMAB, and SCPH
Should you be buying ProQR Therapeutics stock or one of its competitors? The main competitors of ProQR Therapeutics include Gossamer Bio (GOSS), Skye Bioscience (SKYE), Seres Therapeutics (MCRB), Prelude Therapeutics (PRLD), Capricor Therapeutics (CAPR), Incannex Healthcare (IXHL), CervoMed (CRVO), Greenwich LifeSciences (GLSI), I-Mab (IMAB), and scPharmaceuticals (SCPH). These companies are all part of the "pharmaceutical preparations" industry.
ProQR Therapeutics (NASDAQ:PRQR) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.
ProQR Therapeutics received 180 more outperform votes than Gossamer Bio when rated by MarketBeat users. However, 65.16% of users gave Gossamer Bio an outperform vote while only 61.95% of users gave ProQR Therapeutics an outperform vote.
Gossamer Bio has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -431.65%. ProQR Therapeutics' return on equity of -56.71% beat Gossamer Bio's return on equity.
ProQR Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500.
ProQR Therapeutics has higher revenue and earnings than Gossamer Bio. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by insiders. Comparatively, 5.0% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
ProQR Therapeutics currently has a consensus target price of $3.60, indicating a potential upside of 80.00%. Gossamer Bio has a consensus target price of $7.65, indicating a potential upside of 912.71%. Given Gossamer Bio's higher possible upside, analysts plainly believe Gossamer Bio is more favorable than ProQR Therapeutics.
In the previous week, Gossamer Bio had 15 more articles in the media than ProQR Therapeutics. MarketBeat recorded 19 mentions for Gossamer Bio and 4 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 0.67 beat Gossamer Bio's score of 0.29 indicating that ProQR Therapeutics is being referred to more favorably in the media.
Summary
ProQR Therapeutics beats Gossamer Bio on 9 of the 16 factors compared between the two stocks.
Get ProQR Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProQR Therapeutics Competitors List
Related Companies and Tools
